Skip Navigation Change Font Size

Audit (A-01-11-02509)

09-24-2012
Axerion Therapeutics Generally Claimed Allowable Recovery Act Grant Costs

Executive Summary

Axerion Therapeutics (the grantee) claimed costs of $951,000 that were allowable under the terms of the grant and applicable Federal regulations; however, the grantee did not account for $54,000 in proceeds that it earned from the sale of equipment that was purchased for the grant. The National Institutes of Health awarded the grantee $3 million under the American Recovery and Reinvestment Act of 2009.

Complete Report

Download the complete report

Adobe® Acrobat® is required to read PDF files.

I'm Looking For

Let's start by choosing a topic

Exclusions Database Report Fraud
Newsletter Sign Up Envelop Graphic

Stay up to date on the latest OIG news and opinions

Office of Inspector General, U.S. Department of Health and Human Services | 330 Independence Avenue, SW, Washington, DC 20201